Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Corient Private Wealth LLC

Corient Private Wealth LLC lifted its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 91.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 10,200 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,863 shares during the quarter. Corient Private Wealth LLC’s holdings in Jazz Pharmaceuticals were worth $1,734,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Vestal Point Capital LP purchased a new position in Jazz Pharmaceuticals during the second quarter worth approximately $127,344,000. Goldentree Asset Management LP purchased a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at approximately $149,597,000. Franklin Resources Inc. increased its position in shares of Jazz Pharmaceuticals by 164.0% in the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock valued at $309,215,000 after buying an additional 1,129,995 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Jazz Pharmaceuticals by 160.2% during the 4th quarter. Bank of New York Mellon Corp now owns 1,161,857 shares of the specialty pharmaceutical company’s stock worth $197,516,000 after buying an additional 715,361 shares during the period. Finally, Adage Capital Partners GP L.L.C. raised its stake in shares of Jazz Pharmaceuticals by 258.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 548,000 shares of the specialty pharmaceutical company’s stock worth $93,160,000 after buying an additional 395,000 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on JAZZ. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the company from $188.00 to $307.00 in a research note on Tuesday, May 19th. Morgan Stanley restated an “overweight” rating and set a $245.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, May 7th. Barclays lifted their target price on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the company an “overweight” rating in a research report on Wednesday, May 27th. Bank of America boosted their target price on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Finally, Raymond James Financial restated an “outperform” rating and set a $239.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 6th. Sixteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $246.06.

Jazz Pharmaceuticals Stock Up 1.4%

NASDAQ JAZZ opened at $240.97 on Wednesday. The business has a fifty day moving average price of $225.97 and a 200 day moving average price of $193.86. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The company has a market cap of $15.14 billion, a P/E ratio of -12,042.48, a P/E/G ratio of 0.21 and a beta of 0.32. Jazz Pharmaceuticals PLC has a one year low of $105.00 and a one year high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The company had revenue of $1.07 billion for the quarter. Research analysts anticipate that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Heather Ann Mcsharry sold 2,000 shares of the stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.00, for a total value of $482,000.00. Following the completion of the sale, the director owned 18,449 shares in the company, valued at approximately $4,446,209. This represents a 9.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Neena M. Patil sold 1,200 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total transaction of $278,196.00. Following the completion of the transaction, the executive vice president directly owned 51,549 shares in the company, valued at $11,950,604.67. This trade represents a 2.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 7,098 shares of company stock valued at $1,689,086. Corporate insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.